More

Private vs NHS Weight Loss Injections

Compare private vs NHS weight loss injections in the UK, including availability, eligibility, waiting times, and which option may be right for you.

Whether you are weighing up paying for Mounjaro or Wegovy privately, applying for them on the NHS, or wondering whether you might combine the two, this guide compares the two routes — eligibility, cost, waiting times, treatment caps, and what happens to monitoring and follow-up. The right route depends on what you qualify for and what you can wait for. LetsLoseWeight is an independent comparison site; we do not prescribe medication.

The headline difference

The choice between private and NHS weight-loss injections in the UK comes down to four practical differences:

  • Cost — NHS treatment costs only the standard prescription charge (£9.90 in 2025/26 in England; free in Scotland, Wales and Northern Ireland). Private treatment costs £130–£300 per month depending on dose and provider.
  • Eligibility — NHS criteria are tighter than the licensed indication. Private criteria match the licensed indication.
  • Waiting times — Private prescribing turnaround is days. NHS access can take weeks to months depending on the route and your area.
  • Treatment cap — NHS Wegovy is capped at 2 years per NICE TA875. NHS Mounjaro under NICE TA1026 is not capped at 2 years. Private treatment has no fixed cap.

NHS route — Wegovy under TA875

NHS Wegovy is funded under NICE TA875, published in March 2023. The eligibility criteria as set by NICE:

  • BMI ≥35 with at least one weight-related comorbidity (or BMI ≥30 in some specific groups, e.g. people from particular ethnic backgrounds with a higher risk profile)
  • Access through a specialist weight management service (Tier 3 or above)
  • Treatment is capped at 2 years maximum

NICE's 2-year cap reflected the available efficacy and cost-effectiveness data at the time of appraisal. After 2 years, patients either switch to private treatment, switch to a different NHS pathway, or stop.

Practical issues: NHS Tier 3 weight management services are oversubscribed in many areas. Waiting lists of 6–18 months were common in 2024–2025. Capacity is improving but uneven across the country.

NHS route — Mounjaro under TA1026

NHS Mounjaro is funded under NICE TA1026, published in December 2024. Eligibility criteria:

  • BMI ≥35 with at least 3 weight-related comorbidities, OR BMI ≥40 with at least one weight-related comorbidity
  • Access primarily through primary care (GPs), with phased rollout
  • No 2-year cap — long-term continuation is possible

The phased rollout means Mounjaro is being introduced into NHS prescribing gradually. As of this guide's last review, not all areas were yet able to prescribe NHS Mounjaro. Check with your GP or local CCG/ICB.

The NHS Mounjaro criteria are tighter than NHS Wegovy criteria — typically reserved for higher BMI plus more comorbidities. This reflects NICE's cost-effectiveness assessment given Mounjaro's pricing.

Private route — Mounjaro and Wegovy

Private weight-loss injections are available through GPhC-registered pharmacies after a clinical assessment. The eligibility threshold matches the licensed indication:

  • Adults with BMI ≥30, or
  • Adults with BMI ≥27 with at least one weight-related comorbidity (e.g. type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea)

Private prescribers may apply tighter criteria as a matter of clinical judgement, but they are working within the licensed indication, which is broader than NHS criteria.

Private treatment has no fixed time limit. Continuation depends on clinical review and the patient's ongoing wish to continue.

Cost comparison over a typical course

For someone on Mounjaro 12.5mg at the maintenance dose:

  • NHS: £9.90 prescription charge per month (England) or free (Scotland/Wales/NI). Annual cost: ~£120 (England) or £0 elsewhere.
  • Private: ~£250 per month at typical pricing. Annual cost: ~£3,000.

Over 2 years that is roughly £240 vs £6,000 — a difference of £5,760.

For Wegovy 2.4mg, the equivalent figures are very similar. The private–NHS gap is the main driver of why patients eligible for NHS treatment generally take it.

When private is the right choice

Private treatment makes sense if:

  • You don't meet NHS criteria but do meet the licensed indication. Many patients fall into this gap — eligible privately, not eligible on NHS.
  • You are eligible but the wait is too long. NHS specialist services in some areas have waits long enough that paying privately for 6–12 months while waiting can be a reasonable choice.
  • You want the broader range of dose options — private prescribers have full access to all licensed doses, while NHS pathways may have limitations.
  • Your NHS area doesn't yet offer it. Mounjaro NHS rollout is uneven. Wegovy access depends on specialist service availability.
  • You want continuity beyond NHS limits — for Wegovy specifically, NHS treatment is capped at 2 years; some patients move to private to continue.

When NHS is the right choice

NHS treatment makes sense if:

  • You meet the criteria — particularly the higher BMI and comorbidity thresholds for either TA.
  • You can wait for the specialist or primary-care assessment.
  • You want integrated wraparound care — NHS Tier 3 services include dietetic, behavioural, and sometimes psychological support that goes beyond what most private providers offer.
  • You want lower cost as a primary factor — the difference is several thousand pounds per year.

For many patients meeting NHS criteria, NHS is unambiguously the better route. The specialist service support is real and valuable, the cost is much lower, and the medicine itself is identical.

Combining private and NHS routes

Some patients use private treatment as a bridge to NHS treatment — paying privately while on a waiting list, then switching to NHS once a place becomes available. This is workable and reasonably common. Things to be aware of:

  • Disclose to both providers. The NHS prescriber needs to know what dose you have reached privately to continue without restarting titration.
  • Disclose past private treatment when applying for NHS access — most services accept ongoing private treatment as part of the picture, and concealing it complicates the clinical record.
  • Keep documentation — you may need to provide proof of private prescription, dose history, and dispensing pharmacy details.

Combining is harder for Wegovy specifically

The NHS Wegovy 2-year cap creates a particular issue. After 2 years on NHS Wegovy, you would need to switch to private if you wished to continue. Some patients plan for this from the start; others find it logistically difficult to manage at the time. Worth thinking through before NHS treatment starts.

NHS Mounjaro under TA1026 does not carry the same cap, so this issue does not arise for tirzepatide.

What's the same regardless of route

The medicine itself is identical through either route — same manufacturer, same regulatory licence, same supply chain. What differs is the wraparound:

  • Clinical assessment depth — NHS specialist services typically include more detailed assessment than online private services
  • Monitoring frequency — varies between providers in both routes
  • Behavioural and dietetic support — NHS Tier 3 services tend to include this; private providers vary
  • Continuity — NHS care is long-term and integrated; private care depends on the provider you have chosen

The medicine itself is not better in one route than the other. The total package of care can be.

What if I want both?

Some patients want to use NHS access for the medicine and private care for additional services (more frequent reviews, dedicated dietetics, etc.). This is workable, but the NHS prescriber needs to know what private support you are using to avoid duplication or interactions.

There is no rule against combining NHS prescription with private support services. The opposite — using private medicine alongside NHS support — is harder, because NHS services typically assume you are also receiving NHS prescriptions.

Frequently asked questions

Can I get Mounjaro or Wegovy on the NHS just by asking my GP?
Sometimes, depending on the medicine and your area. NHS Mounjaro under TA1026 is in primary care but the rollout is phased — many areas don't yet prescribe it. NHS Wegovy under TA875 is through specialist services, not directly through GPs. Check with your GP about local arrangements.

How long is the NHS wait?
Highly variable by area. For NHS Wegovy through Tier 3 weight management services, 6–18 months was common in 2024–2025, with some areas longer. For NHS Mounjaro through primary care, the wait depends on whether your area has implemented the phased rollout. Things are changing fast — ask locally.

Will the NHS pay for me to switch from Wegovy to Mounjaro after the 2-year cap?
Possibly, if you meet the (different and tighter) NHS Mounjaro eligibility criteria. Many patients who meet TA875 do not meet TA1026, and switching pathways is not automatic. This is worth discussing with your prescriber as the 2-year point approaches.

Is private treatment "second class" compared with NHS?
No. The medicine is identical, the regulator is the same (MHRA), and many of the prescribers in private services also work in the NHS. The wraparound services differ, but the prescription itself is just as legitimate.

Can I claim back private weight-loss injection costs through private medical insurance?
Most UK private medical insurance policies exclude weight-loss medication. Some employer schemes are starting to cover it, particularly where weight-related conditions are part of a broader benefits package. Check your policy directly.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. NHS access criteria and rollout vary by area; check locally for the latest position.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Prices
Private vs NHS Weight Loss Injections UK: Compare | LetsLoseWeight